These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12594447)

  • 1. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
    Jain P; Massie BM; Gattis WA; Klein L; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S3-17. PubMed ID: 12594447
    [No Abstract]   [Full Text] [Related]  

  • 2. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
    Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
    Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapeutic choices in the management of acute congestive heart failure.
    Young JB
    Rev Cardiovasc Med; 2001; 2 Suppl 2():S19-24. PubMed ID: 12439358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-type natriuretic peptide: from bench to bedside.
    Adams KF; Mathur VS; Gheorghiade M
    Am Heart J; 2003 Feb; 145(2 Suppl):S34-46. PubMed ID: 12594450
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing outcomes in the patient with acute decompensated heart failure.
    Mehra MR
    Am Heart J; 2006 Mar; 151(3):571-9. PubMed ID: 16504617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic therapy for acute heart failure.
    Tang WH
    Cardiol Clin; 2007 Nov; 25(4):539-51; vi. PubMed ID: 18063158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
    Heywood JT; Khan TA
    Rev Cardiovasc Med; 2007; 8 Suppl 5():S22-9. PubMed ID: 18192950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

  • 12. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
    Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
    Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic stabilization and management of acute heart failure syndromes in the emergency department.
    Kirk JD; Parissis JT; Filippatos G
    Heart Fail Clin; 2009 Jan; 5(1):43-54, vi. PubMed ID: 19026385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of heart failure: a brief review and selected update.
    Unzek S; Francis GS
    Cardiol Clin; 2008 Nov; 26(4):561-71. PubMed ID: 18929231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapies for heart failure.
    Riggs JM
    RN; 2004 Mar; 67(3):28-32; quiz 33. PubMed ID: 15065491
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
    Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.